Suppr超能文献

一名临床及生化诊断为肢端肥大症患者的空蝶鞍

EMPTY SELLA IN A PATIENT WITH CLINICAL AND BIOCHEMICAL DIAGNOSIS OF ACROMEGALY.

作者信息

Bestepe N, Aydin C, Tam A A, Ercan K, Ersoy R, Cakir B

机构信息

Ankara City Hospital, Dept. of Endocrinology and Metabolism, Ankara, Turkey.

"Yildirim Beyazit" University, Faculty of Medicine, Dept. of Endocrinology and Metabolism, Ankara, Turkey.

出版信息

Acta Endocrinol (Buchar). 2022 Jan-Mar;18(1):97-101. doi: 10.4183/aeb.2022.97.

Abstract

BACKGROUND

Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Empty sella (ES) is an anatomical condition of sella turcica that is partially or completely filled with cerebrospinal fluid mainly due to intrasellar herniation of subarachnoid space. Here, we describe a patient who presented with clinical and biochemical features of acromegaly and who had an ES on pituitary magnetic resonance imaging (MRI).

CASE REPORT

A 73-year-old male patient was consulted in our clinic because of the acromegalic phenotype while planning for colorectal adenocarcinoma surgery. The patient noticed gradual enlarging of his hands, feet and nose for 30 years, but never consulted to any clinician for this reason. Serum GH was 20.6 ng/mL (normal <3 ng/mL) and IGF-1 was 531 ng/mL (normal, 69-200 ng/ml). An oral glucose tolerance test showed no suppression of GH values. T1-weighted MRI revealed an ES. 18F-FDG PET/CT and Ga-DOTATADE PET/CT did not show any finding consistent with ectopic GH secretion. Growth hormone releasing hormone (GHRH) was within the normal range (<100mg/dL). He was treated with long-acting octreotide 20 mg per 28 days. At the 6 month of treatment, serum GH and IGF-1 levels were decreased to 5.45 ng/mL and 274 ng/mL, respectively.

CONCLUSION

The mechanism underlying the association of acromegaly and ES remains unclear. Apoplexy on existing pituitary adenoma and then formation of necrosis can proceed to ES. Since our patient did not have a history of pituitary apoplexy and we could not find any reason for secondary ES, we considered primary ES.

摘要

背景

肢端肥大症是一种与生长激素(GH)和胰岛素样生长因子-1(IGF-1)过度分泌相关的后天性疾病。空蝶鞍(ES)是蝶鞍的一种解剖学状态,主要由于蛛网膜下腔向鞍内疝入,蝶鞍部分或完全被脑脊液填充。在此,我们描述一名患者,其具有肢端肥大症的临床和生化特征,且垂体磁共振成像(MRI)显示有空蝶鞍。

病例报告

一名73岁男性患者在计划进行结肠直肠腺癌手术时,因肢端肥大症表型前来我院就诊。患者注意到其手部、足部和鼻子逐渐增大已有30年,但从未因此咨询过任何临床医生。血清GH为20.6 ng/mL(正常<3 ng/mL),IGF-1为531 ng/mL(正常,69 - 200 ng/ml)。口服葡萄糖耐量试验显示GH值未被抑制。T1加权MRI显示有空蝶鞍。18F-FDG PET/CT和Ga-DOTATADE PET/CT未显示任何与异位GH分泌一致的发现。生长激素释放激素(GHRH)在正常范围内(<100mg/dL)。他接受了每28天20 mg长效奥曲肽的治疗。在治疗6个月时,血清GH和IGF-1水平分别降至5.45 ng/mL和274 ng/mL。

结论

肢端肥大症与空蝶鞍关联的潜在机制仍不清楚。现有的垂体腺瘤发生卒中,随后形成坏死,可发展为空蝶鞍。由于我们的患者没有垂体卒中病史,且我们找不到继发性空蝶鞍的任何原因,我们考虑为空蝶鞍综合征。

相似文献

2
Acromegaly with empty sella syndrome.肢端肥大症合并空蝶鞍综合征。
Endocrinol Diabetes Metab Case Rep. 2021 Jul 1;2021. doi: 10.1530/EDM-21-0049.

本文引用的文献

1
Acromegaly: clinical features at diagnosis.肢端肥大症:诊断时的临床特征
Pituitary. 2017 Feb;20(1):22-32. doi: 10.1007/s11102-016-0772-8.
3
Acromegaly: an endocrine society clinical practice guideline.肢端肥大症:内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. doi: 10.1210/jc.2014-2700. Epub 2014 Oct 30.
4
Empty sella syndrome - beyond being an incidental finding.空蝶鞍综合征——不仅仅是一个偶然发现。
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S321-3. doi: 10.4103/2230-8210.104075.
7
Acromegaly with no pituitary adenoma and no evidence of ectopic source.无垂体腺瘤且无异位来源证据的肢端肥大症。
Indian J Endocrinol Metab. 2011 Sep;15 Suppl 3(Suppl3):S250-2. doi: 10.4103/2230-8210.84878.
8
Acromegaly without imaging evidence of pituitary adenoma.肢端肥大症,影像学未见垂体腺瘤证据。
J Clin Endocrinol Metab. 2010 Sep;95(9):4192-6. doi: 10.1210/jc.2010-0570. Epub 2010 Jul 7.
10
Guidelines for acromegaly management: an update.肢端肥大症管理指南:更新版
J Clin Endocrinol Metab. 2009 May;94(5):1509-17. doi: 10.1210/jc.2008-2421. Epub 2009 Feb 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验